Ohr Pharmaceuticals has completed the enrollment of its OHR-022 phase II clinical trial evaluating its treatment of we age-related macular degeneration (AMD), Squalamine eye drops.
New York-Ohr Pharmaceutical has completed the enrollment of its OHR-002 phase II clinical trial evaluating its treatment of wet age-related macular degeneration (AMD), Squalamine eye drops.
The study has enrolled 142 patients, and the company expects to announce interim data on the first 60 patients completing the protocol in June. Final data are expected in the first calendar quarter of 2015.
“I am pleased with the continued progress of this important study and look forward to the upcoming panned interim analysis,” said Jeffrey S. Heier, MD, director of the vitreoretinal service at Ophthalmic Consultants of Boston, and member of Ohr’s scientific advisory board. “A topical therapeutic would offer an important alternative for the large wet AMD patient population currently being treated with frequent intravitreal injections.”
“We are very encouraged by the interest shown by both patients and physicians in this trial and believe our eye drop formulation . . . has the potential to be a valuable new treatment for wet AMD,” said Irach B. Taraporewala, PhD, chief executive officer of Ohr.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.